PIA
ANIK icon

Piedmont Investment Advisors’s Anika Therapeutics ANIK Stock Holding History

Piedmont Investment Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3,430
Closed -$110K – 1100
2018
Q2 		$110K Buy
+3,430
New +$141K 0.01% 1075

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Piedmont Investment Advisors's ANIK Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Anika Therapeutics (ANIK) in Q3 2018, closing a stake of 3,430 shares — an estimated $110K sold.

Piedmont Investment Advisors first reported a position in ANIK in Q2 2018 and held it in 1 quarter. The position peaked at $110K in Q2 2018. 161 funds tracked by Wall St. Rank hold ANIK as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Anika Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 3,430 Anika Therapeutics shares in Q3 2018, an estimated $110K.
  • Piedmont Investment Advisors first reported a position in Anika Therapeutics in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Anika Therapeutics position peaked at $110K in Q2 2018.
  • 161 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.